What Is Follistatin? A Myostatin-Pathway Research Overview

Follistatin is a naturally occurring secreted glycoprotein that binds and inhibits several members of the transforming growth factor beta (TGF-β) superfamily — most notably myostatin (GDF-8) and activin — and is studied as a negative regulator of these signaling pathways in muscle and tissue biology. Follistatin-344 (FS-344) is a commonly studied isoform/variant used in preclinical muscle research. This article summarizes published animal and in-vitro findings only. Follistatin is described here strictly as a research material; it is for research use only (RUO) and is not a drug, supplement, or product intended for human use.

Quick facts

• Class: secreted glycoprotein; activin-binding protein in the TGF-β superfamily.
• Primary research targets: myostatin (GDF-8) and activin A.
• Research focus: myostatin/activin signaling and skeletal-muscle biology in cell and animal models.
• Common research isoform: Follistatin-344 (FS-344).

What is follistatin?

Follistatin is an endogenous glycoprotein expressed across many tissues. Functionally, it acts as a high-affinity binding protein for certain TGF-β superfamily ligands. By binding these ligands directly, follistatin prevents them from engaging their cell-surface receptors, neutralizing their downstream signaling in laboratory models. Two of the most-studied ligands in this context are myostatin (GDF-8) and activin A — both characterized in research as negative regulators of skeletal-muscle mass. Follistatin-344 (FS-344) is a defined isoform/variant frequently selected in preclinical muscle studies and gene-transfer experiments.

What does the research show?

In published preclinical work, follistatin functions as a dual inhibitor within this pathway. A review in Molecular Endocrinology reported that follistatin is a myostatin-binding protein that can inhibit myostatin activity in vitro and promote muscle growth in vivo, and presented genetic evidence in mice that follistatin also regulates activin A, which works alongside myostatin to limit muscle mass in animal models. A separate study in PNAS used a single administration of an adeno-associated virus (AAV) vector carrying follistatin-344 in mice and reported sustained changes in muscle in both healthy and dystrophic mouse models over multi-month evaluation periods. Research has also highlighted species differences: a Nature Communications study found that activin A is a more prominent regulator of muscle mass than GDF-8 in primates. All of these findings are restricted to in-vitro systems and laboratory animals.

Mechanisms studied in the lab

• Myostatin (GDF-8) binding: follistatin binds myostatin and blocks its interaction with activin type II receptors in cell models.
• Activin binding: follistatin also binds and neutralizes activin A, a second negative regulator in the same axis.
• TGF-β pathway modulation: by sequestering these ligands, follistatin reduces downstream SMAD-mediated signaling associated with these specific TGF-β superfamily members in preclinical systems.

Research status

Follistatin and Follistatin-344 are research materials. They are not approved by the FDA for the diagnosis, treatment, cure, or prevention of any condition, and are not dietary supplements or human/veterinary therapeutics. The findings above come from in-vitro experiments and animal studies; they do not establish any effect, benefit, or safety profile in humans.

Related research peptides

Bolt Peptide does not currently stock follistatin. To browse the research materials we do carry, visit our research peptide catalog. For a related topic in growth and muscle-tissue signaling, see our overview of IGF-1 LR3.

FAQ

Is follistatin the same as Follistatin-344? Follistatin-344 (FS-344) is a specific isoform/variant of the broader follistatin protein, one of the forms most commonly referenced in preclinical muscle-research literature.

How does follistatin relate to myostatin? In research models, follistatin binds myostatin (GDF-8) and blocks its signaling. Because follistatin also binds activin, studies describe it as inhibiting more than one negative regulator within the TGF-β pathway.

Is follistatin approved for human use? No. It is described here as a research-use-only material, not an approved drug or supplement, and not for human consumption.

References

1. Lee S-J, et al. Regulation of muscle mass by follistatin and activins. Mol Endocrinol. 2010.
2. Haidet AM, et al. Long-term enhancement of skeletal muscle by single gene administration of myostatin inhibitors (AAV1-FS-344). PNAS. 2008.
3. Latres E, et al. Activin A more prominently regulates muscle mass in primates than does GDF8. Nat Commun. 2017.

For research use only. Not for human or veterinary use; not FDA-approved. Statements have not been evaluated by the FDA.